Ph.D. University of California, Berkeley
1. Antibody engineering: We are engineering and investigating bispecific antibodies to deliver nanomedicines into cancer cells for improved anticancer selectivity and efficacy.
2. Nanomedicine: New approaches to stably load and retain hydrophobic drugs in liposomal nanocarriers are under development.
3. Directed molecular evolution: We perform directed molecular evolution of human enzymes for antibody-directed enzyme prodrug therapy.
4. Prodrug therapy: Anticancer prodrugs that are selectively activated in the tumor microenvironment are under investigation to improve the selectivity and therapeutic efficacy of cancer treatment.
5. Anti-PEG antibodies: We develop antibodies to assay PEGylated drugs in human serum and are extending these studies to investigating the impact of pre-existing and induced anti-PEG antibodies on the therapeutic efficacy and safety of PEGylated medicines.
2017 MOST Outstanding Research Award
2018 14th Tien Te Lee Outstanding Award (14th永信李天德醫藥科技)
2018 25th TECO Technology Foundation’s Outstanding Achievement Award in Biomedical Technology (第二十五屆東元獎)
2019 Ministry of Economic Affairs 6th National Industrial Innovation Award (第6屆經濟部國家產業創新獎個人類獎項)
2020 MOST Outstanding Research Award
2022 Outstanding Research Award of the Taiwan Nanomedicine Society
2022 Ministry of Education’s 63rd Annual Academic Award (63屆教育部學術獎)